New T‑cell therapy targets three tumor proteins, shows early survival gains in aggressive pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National Hospital using a ...
Healio

Remibrutinib helps adults with chronic inducible urticaria achieve symptom control

More adults with chronic inducible urticaria receiving remibrutinib vs. placebo achieved complete symptom control at week 12, ...
MPR

New Pen Formulation of Besremi Approved for Polycythemia Vera

The new presentation is expected to provide an additional self-administration option for patients with polycythemia vera.
Interesting Engineering

US plans to quadruple THAAD interceptor output under new $35 billion deal

Lockheed Martin secures a potential $35 billion THAAD contract to quadruple interceptor production and speed deliveries to ...
News-Medical.Net

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new ...
Monthly Prescribing Reference

FDA Accepts Replimune’s RP1 Resubmission for Advanced Melanoma

The FDA has designated the filing as a complete, Class 1 response with a PDUFA target action date of August 2, 2026. The Food and Drug Administration (FDA) has accepted for review Replimune’s ...